<div id="readability-page-1"><div><p>Over the last 7 days, the United States market has dropped 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth prospects.</p><h3>Top 10 Undervalued Stocks Based On Cash Flows In The United States</h3><div><table><tbody><tr><td><strong>Name</strong></td><td><strong>Current Price</strong></td><td><strong>Fair Value (Est)</strong></td><td><strong>Discount (Est)</strong></td></tr><tr><td>Solstice Advanced Materials (SOLS)</td><td>$81.02</td><td>$156.32</td><td>48.2%</td></tr><tr><td>Robert Half (RHI)</td><td>$31.26</td><td>$60.09</td><td>48%</td></tr><tr><td>Rayonier (RYN)</td><td>$20.97</td><td>$40.79</td><td>48.6%</td></tr><tr><td>MercadoLibre (MELI)</td><td>$1607.80</td><td>$3085.44</td><td>47.9%</td></tr><tr><td>Live Oak Bancshares (LOB)</td><td>$37.41</td><td>$74.21</td><td>49.6%</td></tr><tr><td>Lazard (LAZ)</td><td>$46.36</td><td>$91.21</td><td>49.2%</td></tr><tr><td>Inter &amp; Co (INTR)</td><td>$5.67</td><td>$10.91</td><td>48%</td></tr><tr><td>Cactus (WHD)</td><td>$56.62</td><td>$111.45</td><td>49.2%</td></tr><tr><td>BlackSky Technology (BKSY)</td><td>$34.76</td><td>$68.23</td><td>49.1%</td></tr><tr><td>AbbVie (ABBV)</td><td>$227.23</td><td>$444.25</td><td>48.9%</td></tr></tbody></table></div><p>Click here to see the full list of 140 stocks from our Undervalued US Stocks Based On Cash Flows screener.</p><p>Let's take a closer look at a couple of our picks from the screened companies.</p><h2>Travere Therapeutics (TVTX)</h2><p><strong>Overview:</strong> Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States, with a market cap of $4.26 billion.</p><p><strong>Operations:</strong> The company's revenue is primarily derived from the development and commercialization of innovative therapies, amounting to $536.20 million.</p><p><strong>Estimated Discount To Fair Value:</strong> 46.6%</p><p>Travere Therapeutics appears undervalued based on cash flow analysis, trading at US$45.81 compared to a future cash flow value estimate of US$85.85. Despite recent insider selling and share price volatility, the company shows strong revenue growth potential at 22.4% annually, outpacing the market's 11.8%. Recent FDA approval for FILSPARI in treating FSGS expands its addressable market significantly, potentially enhancing future cash flows and profitability projections over the next three years.</p><ul><li>The analysis detailed in our Travere Therapeutics growth report hints at robust future financial performance.</li><li>Unlock comprehensive insights into our analysis of Travere Therapeutics stock in this financial health report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>TVTX Discounted Cash Flow as at Jun 2026</figcaption></figure><h2>Goosehead Insurance (GSHD)</h2><p><strong>Overview:</strong> Goosehead Insurance, Inc. operates as a holding company for Goosehead Financial, LLC, offering personal lines insurance agency services in the United States with a market cap of approximately $1.37 billion.</p><p><strong>Operations:</strong> The company's revenue primarily comes from its insurance distribution segment, which generated $382.20 million.</p><p><strong>Estimated Discount To Fair Value:</strong> 42%</p><p>Goosehead Insurance is trading at US$38.35, below its future cash flow value estimate of US$66.13, suggesting undervaluation. The company reported Q1 2026 revenue of US$93.08 million and net income of US$4.89 million, reflecting strong financial performance with earnings growth outpacing the market at 21.7% annually versus 16.8%. Despite high debt levels and negative equity, significant share buybacks totaling US$131.51 million may enhance shareholder value moving forward.</p><ul><li>Our comprehensive growth report raises the possibility that Goosehead Insurance is poised for substantial financial growth.</li><li>Delve into the full analysis health report here for a deeper understanding of Goosehead Insurance.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a5f09225-d683-4366-a9bc-a20145f11454/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a5f09225-d683-4366-a9bc-a20145f11454/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>GSHD Discounted Cash Flow as at Jun 2026</figcaption></figure><h2>National Bank Holdings (NBHC)</h2><p><strong>Overview:</strong> National Bank Holdings Corporation, with a market cap of $1.89 billion, operates as the bank holding company for NBH Bank, offering a range of banking products and financial services to commercial, business, and consumer clients in the United States.</p><p><strong>Operations:</strong> The company's revenue primarily comes from its banking segment, which generated $429.18 million.</p><p><strong>Estimated Discount To Fair Value:</strong> 21.2%</p><p>National Bank Holdings is trading at US$42.19, below its estimated future cash flow value of US$53.51, indicating it is undervalued by over 20%. The company's earnings are forecast to grow significantly at 30.7% annually, surpassing the US market average. Recent financials show net interest income increased to US$108.8 million in Q1 2026, though net income decreased to US$20.79 million from a year ago. A recent buyback of shares worth $16.11 million may support shareholder value despite past dilution concerns.</p><ul><li>Our earnings growth report unveils the potential for significant increases in National Bank Holdings' future results.</li><li>Navigate through the intricacies of National Bank Holdings with our comprehensive financial health report here.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e2e7225-a0e6-47c3-8635-c7104af5c872/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e2e7225-a0e6-47c3-8635-c7104af5c872/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>NBHC Discounted Cash Flow as at Jun 2026</figcaption></figure><h2>Summing It All Up</h2><ul><li>Get an in-depth perspective on all 140 Undervalued US Stocks Based On Cash Flows by using our screener here.</li><li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li><li>Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.</li></ul><h2>Ready For A Different Approach?</h2><ul><li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li><li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li><li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.      It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

SOLS

NBHC

TVTX

MELI

GSHD

KMLI

<p>Simply Wall St identifies US stocks potentially undervalued by June 2026 based on cash flow analysis. Highlighted picks include Travere Therapeutics (TVTX), Goosehead Insurance (GSHD), and National Bank Holdings (NBHC), all trading below estimated fair value with strong earnings growth forecasts. The article also lists other top undervalued stocks like Solstice Advanced Materials and MercadoLibre, suggesting investment opportunities amidst market volatility.</p>

3 Stocks That May Be Priced Below Their Estimated Value In June 2026